Clinical Study on Protective Effect of Xinmaitong Capsule(心脉通胶囊) on Damage of Vascular Endothelial Cells

Objective: To assess the effect of Xinmaitong (XMT) capsule in treating coronary heart disease (CHD).Methods: The 38 patients of coronary heart disease with myocardial ischemia were divided randomly into XMT group (20 cases) and control group (18 cases). Conventional western medical therapy was given to both groups and the XMT group received XMT treatment in addition. The changes of endothelin (ET) and calcitonin gene related peptide (CGRP) levels, ST segment of ECG and clinical symptoms after treatment in all the patients were observed. 14 healthy persons were taken as normal control.Results: The ET level of all patients was significantly higher than that of normal control ( P <0.001), and level of CGRP in patients was not significantly different from normal ( P >0.05). After treatment, results showed that: (1) The ET levels and the scores of clinical symptoms of both groups decreased significantly ( P <0.01), and the depressed ST segment elevated markedly ( P <0.01) as compared with that before treatment, and the changes revealed more evidently in XMT group in comparison with those in the control group ( P <0.05～0.01). (2) The level of CGRP was significantly increased in XMT group ( P <0.01) while it was unchanged in the control group ( P >0.05).Conclusion: There is a severe damage of vascular endothelial cells (VEC) in patients of coronary heart disease. XMT could not only reduce significantly the plasma ET content, but also enhance markedly the production and release of CGRP, so it has a good anti ischemic effect, which may be closely correlated with its action on improving the function of VEC and regulating metabolism of ET and CGRP.

Clinical Study on Protective Effect of Xinmaitong Capsule on Damage of Vascular Endothelial Cells

Objective: To assess the effect of Xinmaitong (XMT) capsule in treating coronaryheart disease (CHD). Methods: Thirty-eightpatients of coronary heart disease with myocardial ischemia were divided randomly intoXMT group (20 cases) and control group (18cases). Conventional western medical therapywas given to both groups and the XMT groupreceived additional XMT treatment. Thechanges of endothelin (ET ) and calcitoningene-related peptide (CGRP) levels, ST segment of ECG and clinical symptoms aftertreatment in all the patients were observed.Data of 14 healthy persons were taken as normal control. Results: The ET level of all patients was significantly higher than that of thenormal control (P < 0. 001 ), and level ofCGRP in patients was not different from normal control significantly (P > 0. 05 ). Aftertreatment, results showed that: (1 ) The ETlevels and the scores of clinical symptoms ofboth groups decreased significantly (P <0. 01 ), and ST segment elevated markedly(P< 0. 01) as compared with before treatment, and the changes revealed more evidentin XMT group in comparison with those of thecontrol group (P < 0.05 - 0.01 ). (2 ) Thelevel of CGRP was significantly increased inXMT group (P < 0. 01 ) while unchanged inthe control group (P > 0. 05 ). Conclusions:There is severe damage of vascular endothelialcells in CHD patients. XMT could not only reduce significantly the plasma ET content, butalso enhance markedly the production and release of CGRP, so it has a good anti--ischemiceffect, which may be closely related with itsaction on improving the function of vascularendothelial cells and regulating metabolism ofET and CGRP.